Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) Interest Expenses (2016 - 2023)

Historic Interest Expenses for Dexcom (DXCM) over the last 15 years, with Q2 2023 value amounting to $5.9 million.

  • Dexcom's Interest Expenses rose 2553.19% to $5.9 million in Q2 2023 from the same period last year, while for Mar 2024 it was $5.9 million, marking a year-over-year decrease of 6827.96%. This contributed to the annual value of $18.6 million for FY2022, which is 106.38% down from last year.
  • As of Q2 2023, Dexcom's Interest Expenses stood at $5.9 million, which was up 2553.19% from $4.6 million recorded in Q1 2023.
  • In the past 5 years, Dexcom's Interest Expenses registered a high of $24.4 million during Q3 2020, and its lowest value of -$42.4 million during Q4 2020.
  • Moreover, its 5-year median value for Interest Expenses was $4.8 million (2021), whereas its average is $7.0 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first surged by 21250.0% in 2019, then plummeted by 37712.42% in 2020.
  • Dexcom's Interest Expenses (Quarter) stood at $15.3 million in 2019, then plummeted by 377.12% to -$42.4 million in 2020, then skyrocketed by 111.08% to $4.7 million in 2021, then changed by 0.0% to $4.7 million in 2022, then grew by 25.53% to $5.9 million in 2023.
  • Its last three reported values are $5.9 million in Q2 2023, $4.6 million for Q1 2023, and $4.7 million during Q4 2022.